Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The potential of amino acid PET imaging for prediction and monitoring of vorasidenib response in IDH-mutant gliomas.

Neuro-oncology - 4 Mar 2024

Albert Nathalie L, Furtner Julia, van den Bent Martin J, Preusser Matthias

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amino Acids
Share to Brain Neoplasms
Share to Diamines
Share to Glioma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Isocitrate Dehydrogenase

Share to Mutation

Share to Positron-Emission Tomography

Share to Pyridines

Source

Open in PubMed Open full text

Identifiers

PMID: 38070497
DOI: 10.1093/neuonc/noad240
PMCID: PMC10911996

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The potential of amino acid PET imaging for prediction and monitoring of vorasidenib response in IDH-mutant gliomas.PMID 38070497Read ↗

Evaluation of early metabolic changes following vorasidenib using FET PET in patients with IDH-mutant gliomasSemantic proximity Read ↗

Clinical applications and prospects of PET imaging in patients with IDH-mutant gliomas.Semantic proximity Read ↗

Amino acid PET imaging to monitor mIDH inhibitor treatments in patients with refractory IDH-mutant gliomas.Semantic proximity Read ↗

Mutated Isocitrate Dehydrogenase (mIDH) as Target for PET Imaging in Gliomas.Semantic proximity Read ↗

Treatment of IDH-mutant glioma in the INDIGO eraSemantic proximity Read ↗

The role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant glioma.Semantic proximity Read ↗

Vorasidenib in IDH1- or IDH2-Mutant Low-Grade GliomaSemantic proximity Read ↗

Advances in IDH-mutant glioma management: IDH inhibitors, clinical implications of INDIGO trial, and future perspectives.Semantic proximity Read ↗

The role of amino-acid PET in the light of the new WHO classification 2016 for brain tumors.Semantic proximity Read ↗

18F-DOPA-PET and Advanced MRI Improve Treatment Response Assessment in IDH1/2-Mutant Gliomas Treated with IDH Inhibitors.Semantic proximity Read ↗

Screening of targets related to amino acid metabolism in glioma to identify the tumor-promoting effects of its core gene ASLSemantic proximity Read ↗

IDH mutation is paradoxically associated with higher 18F-FDOPA PET uptake in diffuse grade II and grade III gliomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.